key: cord-1015923-0uyf388f
authors: Kiyasu, Y.; Akashi, Y.; Sugiyama, A.; Takeuchi, Y.; Notake, S.; Naito, A.; Nakamura, K.; Ishikawa, H.; Suzuki, H.
title: A prospective evaluation of the analytical performance of GENECUBE(R) HQ SARS-CoV-2 and GENECUBE(R) FLU A/B
date: 2021-02-25
journal: nan
DOI: 10.1101/2021.02.24.21252337
sha: 506246196926706b7d9d235ec4477de69f57f55c
doc_id: 1015923
cord_uid: 0uyf388f

Background: Molecular tests are the mainstay for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, their accessibility can be limited by the long examination time and inability to evaluate multiple samples at once. This study evaluated the analytical performance of the newly developed rapid molecular assays GENECUBE(R) HQ SARS-CoV-2 and the GENECUBE(R) FLU A/B. Method: This prospective study was conducted between December 14, 2020, and January 9, 2021, at a polymerase chain reaction (PCR) center. Samples were collected from the nasopharynx with flocked swabs. Molecular tests were performed with the GENECUBE(R) system and reference reverse transcription (RT)-PCR, and the results of the two assays were compared. Result: Among 1065 samples, 81 (7.6%) were positive for SARS-CoV-2 on the reference RT-PCR. Three showed discordance between GENECUBE(R) HQ SARS-CoV-2 and the reference RT-PCR; the total, positive and negative samples of concordance for the two assays were 99.7%, 100%, and 99.7%, respectively. All discordant cases were positive for GENECUBE(R) HQ SARS-CoV-2 and negative for the reference RT-PCR. SARS-CoV-2 was detected from all three samples by another molecular assay for SARS-CoV-2. For the GENECUBE(R) FLU A/B, the total, positive and negative samples of concordance for the two assays were 99.5%, 100%, and 99.1%. Conclusion: The GENECUBE(R) HQ SARS-CoV-2 and GENECUBE(R) FLU A/B demonstrated sufficient analytical performance to detect SARS-CoV-2 and influenza virus A/B.

CoV-2 and the GENECUBE ® FLU A/B.

A prospective comparison between the GENECUBE ® examination and reference realtime polymerase chain reaction (PCR) method was performed with nasopharyngeal samples obtained between December 14, 2020, and January 9, 2021, at a PCR center in Tsukuba, Ibaraki Prefecture, Japan. During the COVID-19 endemic period, sample-collecting for PCR in the Tsukuba district was intensively performed with a drive-through-type method at the PCR center in Tsukuba Medical Center Hospital (TMCH) following a referral from a local public health center and 63 primary care facilities and among healthcare workers at TMCH. Due to the low prevalence rate of influenza and lack of fresh influenza virus-positive samples, we used preserved Universal Transport Medium TM (UTM TM ) samples that had been stored at -80 °C and used in our previous study [13] .

The ethics committee of TMCH approved the present study (approval number: 2020-046), and informed consent was obtained from patients for their participation in the part of the current research using fresh samples.

For sample collections, we obtained a nasopharyngeal sample for PCR with FLOQSwab TM (Copan Italia S.p.A., Brescia, Italy) as previously described [14] . The swab sample was diluted in 3 mL of UTM TM (Copan Italia S.p.A.), and the UTM TM was then transferred to a microbiology laboratory located next to the drive-through sample-collecting place of the PCR center.

After obtaining the UTM TM samples, purification and RNA extraction were performed with a magLEAD 6gC (Precision System Science Co., Ltd., Chiba, Japan) from 200-µL . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 25, 2021. ; https://doi.org/10.1101/2021.02.24.21252337 doi: medRxiv preprint of UTM TM were mixed with 10 μL of protease K solution (Kanto Chemical Co., Inc., Tokyo, Japan) and heated at 65 °C for 5 minutes and 95 °C for 5 minutes. The inactivated samples were diluted with an equal volume of lysis buffer and used for the assay evaluation.

To evaluate the LOD, twelve fresh SARS-CoV-2-positive UTM TM samples obtained within three days before the evaluation were measured for their viral loads and diluted with UTM TM to approximate concentrations of <100 copies/test and <10 copies/test. In total, 24 positive samples were prepared for the evaluation of LODs and measured in quadruplicate for three examination methods: the reference RT-PCR method, GENECUBE ® with the automated purification method, and GENECUBE ® with the heat extraction method. Fresh positive influenza virus UTM TM samples were not obtained during the study, and the LOD study was not performed for GENECUE ® FLU A/B at present. 

The positive concordance rate, negative concordance rate, and total concordance rate is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 25, 2021. ; https://doi.org/10.1101/2021.02.24.21252337 doi: medRxiv preprint of the GENECUBE ® HQ SARS-CoV-2 and GENECUBE ® FLU A/B compared with reference real-time RT-PCR were calculated using the Clopper and Pearson methods with 95% confidence intervals (CIs). All calculations were conducted using the R 3.3.1 software program (The R Foundation, Vienna, Austria).

The results of the LOD evaluation are summarized in Table 1 . The reference RT-PCR correctly detected up to 5 copies/test, while GENECUBE ® with the automated extraction method detected up to 6 copies/test determined by the reference RT-PCR. The LOD of GENECUBE ® with the heat extraction method was 17 copies/test determined by the reference RT-PCR.

During the study period, we evaluated 1065 nasopharyngeal samples. Of these 1065 samples, 486 (45.6%) were obtained from symptomatic patients, and 579 (54.4%) were obtained from asymptomatic patients.

The comparison of the GENECUBE ® HQ SARS-CoV-2 assay with the reference RT-PCR for purified samples is summarized in Table 2a . The total, positive and negative concordance of the two assays were 99.7% (1062/1065), 100% (81/81), and 99.7% (981/984), respectively. Of the three samples with discordance between the two assays, all samples were negative by the reference RT-PCR assay and positive by the GENECUBE ® assay. SARS-CoV-2 was detected from all three samples by the GeneXpert ® for SARS-CoV-2 ( Table 3 ).

The comparison of the GENECUBE ® HQ SARS-CoV-2 assay with the heat extraction method with the reference RT-PCR is summarized in Table 2b . The total, positive and negative . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 25, 2021. ; https://doi.org/10.1101/2021.02.24.21252337 doi: medRxiv preprint concordance of the two assays were 99.7% (1062/1065), 97.5% (79/81), and 99.9% (983/984), respectively. Of the three samples with discordance between the two assays, one sample was negative by the reference RT-PCR assay and positive by the GENECUBE ® assay with the heat extraction method. SARS-CoV-2 was detected from the sample by the GeneXpert ® for SARS-CoV-2. The other two samples were positive by the reference RT-PCR assay and negative by the GENECUBE ® assay with the heat extraction method (Table 3 ).

The results of the pooling testing with the GENECUBE ® HQ SARS-CoV-2 were summarized in Supplementary Table 2a . The GENECUBE ® HQ SARS-CoV-2 showed a positive result for every pooled sample with a low viral load (20/20, 100%) and with a moderate-high viral load (20/20, 100%). Meanwhile, the reference RT-PCR assay was negative in 4 low viral load pooled samples.

The comparison of the GENECUBE ® FLU A/B assay with the reference RT-PCR is summarized in Table 4a is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint respectively. Of the five samples with discordance between the two assays, all samples were positive by the reference RT-PCR assay and negative by the GENECUBE ® FLU A/B assay with heat-extraction method (Table 5) .

In this study, GENECUBE ® HQ SARS-CoV-2 and the GENECUBE ® FLU A/B showed high analytical performance in this study. The total concordance rate in clinical samples was over 99% between the 2 tests. Regarding the GENECUBE ® FLU A/B, the total concordance rate with the reference RT-PCR was 99.5%. The GENECUBE ® HQ SARS-CoV-2 provided is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 25, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 25, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 25, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 25, 2021. ; https://doi.org/10.1101/2021.02.24.21252337 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 25, 2021. ; Table 3 . Detailed data of the five cases with discrepant findings between the three SARS- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 25, 2021. ; https://doi.org/10.1101/2021.02.24.21252337 doi: medRxiv preprint RT-PCR, reverse transcription polymerase chain reaction Data in parentheses is 95% confidence intervals.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 25, 2021. ; https://doi.org/10.1101/2021.02.24.21252337 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 25, 2021. ; https://doi.org/10.1101/2021.02.24.21252337 doi: medRxiv preprint

COVID-19) Situation Reports

Laboratory testing for coronavirus disease (COVID-19) In: suspected human cases: interim guidance. World Health Organization

Diagnostic testing for SARS-CoV-2. In: interim guidance. World Health Organization

COVID-19) Treatment Guidelines. National Institutes of Health

Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2

Multiplex Assays Authorized for Simultaneous Detection of Influenza Viruses and SARS-CoV-2 by FDA